Skip to content
DataLookout
Menu

NCT06228404

Clinical Study of Safety and Efficacy of Enhanced PSMA CAR- T in Refractory CRPC

StatusSuspended
PhaseEarly Phase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗

  1. Stopped Trial status changed: Active, Not Recruiting → Suspended Sponsor's reason: The study is temporarily suspended to align with revised policy requirements. Show 4 more changesShow less
    • Primary completion pushed from Aug 2026 to Jun 2027
    • Eligibility criteria expanded, about 19 words
    • Study completion pushed from Dec 2026 to Dec 2027
    • Secondary endpoints: details revised at 3 of 5 entries
  2. Minor Primary completion pushed from May 2026 to Aug 2026v4
  3. Notable Primary completion date: May 2025 to May 2026v3 Show 5 more changesShow less
    • Primary endpoints: 1 to 3
    • Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: Dec 2025 to Dec 2026
    • Secondary endpoints: 2 to 5
    • Site details revised
  4. Minor Start date changed from estimate of Jan 2024 to Mar 3, 2024v2
  5. Study First Submitted
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

DLT
Timeframe: Within 28 Days After Enhanced autologous PSMA-CAR T Infusion
The National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE V5.0)
Timeframe: Through 6 months after CAR-T cell infusion
Cytokine Release Syndrome (CRS) grading post CAR T cell infusion
Timeframe: Through 6 months after CAR-T cell infusion

Secondary (5)

Efficacy assessment: PSA changes
Efficacy assessment: radiographic Progression-Free Survival (rPFS)
Pharmacokinetics (PK) assessment: expansion of CAR-T cells
Pharmacokinetics (PK) assessment: persistence of CAR T cells
Pharmacodynamics (PD) assessment eg. (Level of IL-6)

Arms and interventions

Enhanced autologous PSMA-CAR T:Experimental

Enhanced autologous PSMA-CAR T is an electrotransfer system based on non-viral transposons that integrates the CAR gene into the genome of host cells by electrotransfer using PMSA as a target, while this CAR vector co-expresses enhanced factors and plays a strong regulatory role in innate and adaptive immunity.

Drugs: Enhanced autologous PSMA-CAR T

Sites

1 site in 1 country

  • Changzheng hospitalShanghai, Shanghai Municipality, China